Previous Article
Full text loading...
薬理と治療
No data available.
Please log in to see this content.
You have no subscription access to this content.
The full text of this article is not currently available.
SGLT2 阻害薬カナグリフロジンの腎保護効果―CREDENCE 試験の結果からわかってきたこと―
JPY
View Affiliations
ライフサイエンス出版
Abstract
The CREDENCE trial provided evidence that patients with type 2 diabetes mellitus and chronic kidney disease treated with canagliflozin have a lower risk of kidney failure and cardiovascular events compared with placebo. In this review, in order to better understand the renoprotective effects of sodium glucose co–transporter 2（SGLT2）inhibitors and their mechanisms, the results of various stratified and exploratory analyses performed on this trial are summarized. （Jpn Pharmacol Ther 2023；51：951‒8）
